Abstract Funding Acknowledgements Type of funding sources: None. Backgrounds Catheter ablation for paroxysmal supraventricular tachycardia (PSVT) is curative treatment. However, diagnosis atrial (AT) distinguishing from other PSVTs are often challenging, especially when the terminates after pacing or does not sustain long enough diagnostic maneuvers. We sought a new method AT. Methods One-hundr...

Electrophysiological and epicardial mapping studies are described in a patient without pre-excitation who had intractable recurrent paroxysmal supraventricular tachycardia. Electrophysiological studies revealed fixed VA conduction times during both rapid ventricular pacing and coupled ventricular stimulation. Catheter mapping of atrial activation during retrograde conduction and during induced ...

Only sinus rhythm electrocardiograms (ECGs) are often available in patients with paroxysmal supraventricular tachycardia (PSVT). However, ECGs have a limited value classifying PSVT types. We aimed to investigate the deep learning approach of Atrioventricular Nodal Reentry Tachycardia (AVNRT) from concealed (AVRT) using ECGs. collected AVNRT or conceald AVRT, and their 12-lead rhythm. The diagno...

The role of simultaneous and sequential atrioventricular (AV) stimulation in prevention of tachyeardia induction, and the underlying electrophysiologic mechanisms involved, were studied in 10 patients with documented paroxysmal reentrant supraventricular tachycardia (PSVT). Reentry circuit was localized to the AV node in seven of 10. The remaining three cases had Wolff-Parkinson-White (WPW) syn...

Plasma concentrations of immunoreactive atrial natriuretic polypeptide were raised in 22 of 23 patients with paroxysmal supraventricular tachycardia and in all seven patients with atrial flutter. Plasma concentrations of atrial natriuretic polypeptide rose soon after the onset of supraventricular tachycardia. A sample taken 30 minutes after reversion to sinus rhythm (pharmacological or non-phar...

BACKGROUND Paroxysmal supraventricular tachycardia (PSVT) has always been a diagnostic and therapeutic challenge for the cardiologists. There are many modalities to treat the problem. Of the available pharmacological treatment, the role of verapamil and adenosine is under debate. This study was carried out to detect and compare the efficacy of both drugs. The objective of this study was to comp...

Paroxysmal supraventricular tachycardia (PSVT) has been a well-recognized clinical syndrome and an electrocardiographically defined arrhythmia since the early days of electrocardiography. The clinical syndrome was defined in European literature in the 19th century. In 1867, Cotton reported on an “unusually rapid action of the heart,” and this was followed by further observations by French and G...

The role of simultaneous and sequential atrioventricular (AV) stimulation in prevention of tachyeardia induction, and the underlying electrophysiologic mechanisms involved, were studied in 10 patients with documented paroxysmal reentrant supraventricular tachycardia (PSVT). Reentry circuit was localized to the AV node in seven of 10. The remaining three cases had Wolff-Parkinson-White (WPW) syn...

Intravenous adenosine triphosphate rapidly terminated all 11 episodes of paroxysmal supraventricular tachycardia in 10 patients. Eight patients reported side effects but these resolved within 20 seconds and did not require treatment. Adenosine triphosphate is a suitable agent for the rapid termination of paroxysmal supraventricular tachycardia.

Paroxysmal Supraventricular Tachycardia (PSVT) treatment requires medically supervised intervention. This is derived from the lack of effective and safe self-administrated for PSVT. Etripamil a novel short-acting calcium channel blocker with rapid intranasal spray shows promising potential unsupervised PSVT, especially in dosage 70 mg. We aim to evaluate efficacy safety acute conversion conduct...